Please login to the form below
FDA approves 14 generic copies of GSK's Coreg
The FDA allows 14 generic manufacturers to sell first generic versions of GlaxoSmithKline's blood pressure drug Coreg in the US
The FDA has given 14 generic manufacturers permission to sell the first generic versions of GlaxoSmithKline's (GSK) blood pressure drug Coreg (carvedilol) on the US market.
The agency stated on 5 September 2007 that the companies, which included Caraco Pharmaceutical, Mylan, Ranbaxy and Watson, could sell generic versions of Coreg in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.
Coregis is approved in the US to treat high blood pressure, mild-to-severe chronic heart failure and left ventricular dysfunction following a heart attack.
GSK sells a newer, daily reformulation of the drug called Coreg CR, which is patent protected until 2023, according to the UK-based firm.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Merck enters agreement with Hanmi for investigational NASH drug
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- OPEN Health at the World Orphan Drug Conference USA
- US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine
- Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month
- Russia becomes first country to approve a COVID-19 vaccine
- Can involving patients in design transform the clinical trial experience?
PMHub
Healthcircle
We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...
Latest intelligence
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
- Can involving patients in design transform the clinical trial experience?
- While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Quick links
Infographics
